Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that endocrinologists and primary care physicians have different rationales driving their choice of prescription antidiabetic drugs. Surveyed primary care physicians (PCPs) are more sensitive to cost and formulary status of antidiabetic agents than are endocrinologists.

"More primary care physicians than endocrinologists cite these two reasons as significant factors that influence their choice of therapies," said Donny Wong, Ph.D., analyst at Decision Resources. "Endocrinologists, on the other hand, are uniformly more concerned about safety and side effects than are primary care physicians."

The new PhysicianForum report entitled Type 2 Diabetes, Part 1: Reassessing the Risks and Treatments also finds that Bristol-Myers Squibb's Glucophage is prescribed as a first-line therapy for the treatment of type 2 diabetes by 93% of endocrinologists and 83% of PCPs. Meanwhile, the recently launched insulin sensitizers, GlaxoSmithKline's Avandia and Takeda's Actos, have begun to surpass the sulfonylureas as physicians' preferred second-line antidiabetic therapy.

Type 2 Diabetes, Part 1: Reassessing the Risks and Treatments is based on a U.S. survey of 17 HMO pharmacy directors, 71 primary care physicians, and 90 endocrinologists. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors. Type 2 Diabetes, Part 2: Current Use, Issues, and Future Desired Design of Single-Pill Combination Agents is also available from Decision Resources, Inc.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high volume-prescribing PCPs, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

GlaxoSmithKline's Marketing Muscle Will be a Major Factor in the Success of Lamictal

View Now